Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Rybelsus (semaglutide) is a brand-name prescription ... If a person has an Original Medicare plan and Part D, they will pay a separate monthly premium for Part D in addition to their Part B ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The expected out-of-pocket costs for commonly used drugs like Eliquis and Ozempic have surged for Medicare beneficiaries in ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

The results of the small study add to evidence that people find drugs like Ozempic and Wegovy helpful to manage cravings for ...